US2002187160A1PendingUtilityA1
Vaccine delivery system
Est. expiryMay 18, 2015(expired)· nominal 20-yr term from priority
A61P 31/10A61P 31/04A61P 37/04A61P 31/12C07K 14/22A61K 39/39A61K 2039/55555A61K 2039/55594A61K 39/095Y10S530/812A61K 39/00Y02A50/30
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to a hyperblebbing strain of Neisseria gonorrhoeae which produces large amounts of blebs useful for production of blebosomes containing antigens for use as a vaccine delivery vehicle or as a diagnostic reagent. The invention also relates to a method for producing high levels of a desired protein in purified form using the hyperblebbing strain of N. gonorrhoeae , and to vaccine delivery systems containing the blebosomes expressing the desired antigen.
Claims
exact text as granted — not AI-modifiedWhat is claimed as new and is desired to be secured by Letters Patent of the United States is:
1 . A vaccine for providing in a subject immunity against a disease, said vaccine comprising blebosomes wherein an immunogenic polypeptide specific for said disease is present in a pharmacologically effective dose in a pharmaceutically acceptable excipient.
2 . The vaccine of claim 1 , wherein the subject is human.
3 . The vaccine of claim 1 , wherein the subject is animal.
4 . The vaccine of claim 1 , wherein said disease is caused by a microorganism.
5 . The vaccine of claim 2 , wherein said disease is caused by a microorganism.
6 . The vaccine of claim 3 , wherein said disease is caused by a microorganism.
7 . The vaccine of claim 1 , wherein said disease is caused by a bacterium.
8 . The vaccine of claim 1 , wherein said disease is caused by a virus.
9 . The vaccine of claim 1 , wherein said disease is caused by a fungus.
10 . The vaccine of claim 1 , wherein said disease is caused by a protozoan.
11 . A pharmaceutical composition for treating a disease, comprising a blebosome wherein a polypeptide active against said disease is present in a pharmacologically effective does in a pharmaceutically acceptable excipient.
12 . The pharmaceutical composition of claim 11 , wherein said polypeptide is a cytokine.
13 . The pharmaceutical composition of claim 11 , wherein said polypeptide is a receptor.
14 . The pharmaceutical composition of claim 11 , wherein said polypeptide is an antibiotic.Join the waitlist — get patent alerts
Track US2002187160A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.